Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Hepatology
•
Hepatology
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
Related Questions
How do you approach HCC screening in patients with advanced fibrosis e.g., F3 on FibroScan?
Do you recommend starting naltrexone at discharge for alcohol use disorder in patients with decompensated cirrhosis secondary to alcohol use?
When would you consider use of EUS guided liver biopsy over percutaneous and/or transjugular?
What is your approach to a patient with "low" liver enzymes?
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
How do you approach dosing beta blockers for variceal prophylaxis when the standard dose doesn’t achieve the target heart rate?"
How do you approach a patient who has incidentally found liver and renal cysts?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
How do you decide whether ordering a 5' nucleotidase or a GGT is the most appropriate option in the evaluation of an elevated alkaline phosphatase?
